Skip to content

Author

S. Scibetta

We have 2 of 21 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis).

INTRODUCTION Conventional Psoriasis Area and Severity Index (PASI) response rates provide a cross-sectional assessment of treatment effectiveness but do not capture the speed, magnitude, and persistence of clinical improvement. This study evaluated the patient-level cumulative clinical benefit of brodalumab over 52 wee...

L. Potestio, S. Corrao, L. Mastorino et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.